CoChat
Sign Up
Cited by 142

The DOI matches its Crossref record.

Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy

Millat, Gilles, Bouvagnet, Patrice, Chevalier, Philippe, Dauphin, Claire, Simon Jouk, Pierre, Da Costa, Antoine, Prieur, Fabienne, Bresson, Jean-Luc, Faivre, Laurence, Eicher, Jean-Christophe, Chassaing, Nicolas, Crehalet, Hervé, Porcher, Raphael, Rodriguez-Lafrasse, Claire, Rousson, Robert·2010·European Journal of Medical Genetics
DOI 10.1016/j.ejmg.2010.07.007
Open this paper in CoChat — free account

Abstract

Hypertrophic Cardiomyopathy (HCM), a common and clinically heterogeneous disease characterized by unexplained ventricular myocardial hypertrophy and a high risk of sudden cardiac death, is mostly caused by mutations in sarcomeric genes but modifiers genes may also modulate the phenotypic expression of HCM mutations. The aim of the current study was to report the frequency of single and multiple gene mutations in a large French cohort of HCM patients and to evaluate the influence of polymorphisms previously suggested to be potential disease modifiers in this myocardial pathology. We report the molecular screening of 192 unrelated HCM patients using denaturing high-performance liquid chromatography/sequencing analysis of the MYBPC3, MYH7, TNNT2 and TNNI3 genes. Genotyping of 6 gene polymorphisms previously reported as putative HCM modifiers (5 RAAS polymorphisms and TNF-α -308 G/A) was also performed. Seventy-five mutations were identified in 92 index patients (48%); 32 were novel. MYBPC3 mutations (25%) represent the most prevalent cause of inherited HCM whereas MYH7 mutations (12%) rank second in the pathogenesis. The onset age was older in patients carrying MYBPC3 mutations than in those with MYH7 mutations. The MYBPC3 IVS20-2A>G splice mutation was identified in 7% of our HCM population. Multiple gene mutations were identified in 9 probands (5%), highlighting the importance of screening other HCM-causing genes even after a first mutation has been identified, particularly in…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ejmg.2010.07.007

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 22

  1. Aoki, 2001, Genetic background in patients with acute myocardial infarction, Jpn. Heart J., 42, 15, 10.1536/jhj.42.15 · DOI
  2. Benjamini, 1995, Controlling the false discovery rate: a new and powerful approach to multiple testing, J. Royal Stat. Soc. Series. B. Stat. Methodol., 57, 289, 10.1111/j.2517-6161.1995.tb02031.x · DOI · Paper page
  3. Bos, 2007, Genetics of hypertrophic cardiomyopathy: one, two, or more diseases?, Curr. Opin. Cardiol., 22, 193, 10.1097/HCO.0b013e3280e1cc7f · DOI
  4. Charron, 1998, Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene, Circulation, 97, 2230, 10.1161/01.CIR.97.22.2230 · DOI
  5. Ehlermann, 2008, Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene, BMC Med. Genet., 9, 95, 10.1186/1471-2350-9-95 · DOI
  6. Erdmann, 2003, Clin. Genet., 64, 339, 10.1034/j.1399-0004.2003.00151.x · DOI
  7. Ingles, 2005, Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling, J. Med. Genet., 42, 10.1136/jmg.2005.033886 · DOI
  8. Kaufman, 2007, RAAS gene polymorphisms influence progression of pediatric hypertrophic cardiomyopathy, Hum. Genet., 122, 515, 10.1007/s00439-007-0429-9 · DOI
  9. Kupari, 1998, Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function, Circulation, 97, 569, 10.1161/01.CIR.97.6.569 · DOI
  10. Marian, 2008, Genetic determinants of cardiac hypertrophy, Curr. Opin. Cardiol., 23, 199, 10.1097/HCO.0b013e3282fc27d9 · DOI
  11. Maron, 1995, Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study, Circulation, 92, 785, 10.1161/01.CIR.92.4.785 · DOI
  12. Morita, 2006, Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham heart study, Circulation, 113, 2697, 10.1161/CIRCULATIONAHA.105.593558 · DOI
  13. Niimura, 1998, Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy, N. Engl. J. Med., 338, 1248, 10.1056/NEJM199804303381802 · DOI
  14. Olivotto, 2008, Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy, Mayo Clin. Proc., 83, 630, 10.1016/S0025-6196(11)60890-2 · DOI
  15. Ortlepp, 2002, Heart, 87, 270, 10.1136/heart.87.3.270 · DOI
  16. Patel, 2000, Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy, J. Mol. Cell. Cardiol., 32, 2369, 10.1006/jmcc.2000.1267 · DOI
  17. Perkins, 2005, Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy, Eur. Heart J., 26, 2457, 10.1093/eurheartj/ehi438 · DOI
  18. Pfeufer, 1996, Angiotensin-converting enzyme and heart chymase gene polymorphisms in hypertrophic cardiomyopathy, Am. J. Cardiol., 78, 362, 10.1016/S0002-9149(96)00296-2 · DOI
  19. Richard, 2003, Hypertrophic cardiomyopathy distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy, Circulation, 107, 2227, 10.1161/01.CIR.0000066323.15244.54 · DOI
  20. Van Driest, 2003, Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy, Circulation, 108, 445, 10.1161/01.CIR.0000080896.52003.DF · DOI
  21. Van Driest, 2004, Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy, J. Am. Coll. Cardiol., 44, 602, 10.1016/j.jacc.2004.04.039 · DOI
  22. Van Driest, 2004, Myosin binding protein c mutations and compound heterozygosity in hypertrophic cardiomyopathy, J. Am. Coll. Cardiol., 44, 1903, 10.1016/j.jacc.2004.07.045 · DOI

Cited by

Sorted by citations

See all 142

Metadata

Authors
Millat, G., Bouvagnet, P., Chevalier, P., Dauphin, C., Simon Jouk, P., Da Costa, A., Prieur, F., Bresson, J.-L., Faivre, L., Eicher, J.-C., Chassaing, N., Crehalet, H., Porcher, R., Rodriguez-Lafrasse, C., & Rousson, R.
Venue
European Journal of Medical Genetics
Publisher
Elsevier BV
Published
2010-09
Volume
53
Issue
5
Pages
261-267
ISSN
1769-7212
DOI
10.1016/j.ejmg.2010.07.007
Cited by
142
References
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review